Viewing Study NCT06757634


Ignite Creation Date: 2025-12-25 @ 2:24 AM
Ignite Modification Date: 2025-12-28 @ 12:05 AM
Study NCT ID: NCT06757634
Status: RECRUITING
Last Update Posted: 2025-06-18
First Post: 2024-12-24
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
Sponsor: Celcuity Inc
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module